- Home
- GRAL vs ORIC Comparison
GRAL vs ORIC Comparison
Compare GRAL & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRAL
- ORIC
- Stock Information
- Founded
- GRAL 2016
- ORIC 2014
- Country
- GRAL United States
- ORIC United States
- Employees
- GRAL N/A
- ORIC N/A
- Industry
- GRAL
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- GRAL
- ORIC Health Care
- Exchange
- GRAL NYSE
- ORIC Nasdaq
- Market Cap
- GRAL 1.3B
- ORIC 362.9M
- IPO Year
- GRAL N/A
- ORIC 2020
- Fundamental
- Price
- GRAL $46.87
- ORIC $10.50
- Analyst Decision
- GRAL Buy
- ORIC Strong Buy
- Analyst Count
- GRAL 3
- ORIC 8
- Target Price
- GRAL $31.50
- ORIC $18.83
- AVG Volume (30 Days)
- GRAL 1.6M
- ORIC 1.1M
- Earning Date
- GRAL 08-12-2025
- ORIC 08-11-2025
- Dividend Yield
- GRAL N/A
- ORIC N/A
- EPS Growth
- GRAL N/A
- ORIC N/A
- EPS
- GRAL N/A
- ORIC N/A
- Revenue
- GRAL $130,711,000.00
- ORIC N/A
- Revenue This Year
- GRAL $19.52
- ORIC N/A
- Revenue Next Year
- GRAL $20.37
- ORIC N/A
- P/E Ratio
- GRAL N/A
- ORIC N/A
- Revenue Growth
- GRAL 30.47
- ORIC N/A
- 52 Week Low
- GRAL $12.33
- ORIC $3.90
- 52 Week High
- GRAL $63.99
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- GRAL N/A
- ORIC 71.20
- Support Level
- GRAL N/A
- ORIC $9.80
- Resistance Level
- GRAL N/A
- ORIC $11.19
- Average True Range (ATR)
- GRAL 0.00
- ORIC 0.61
- MACD
- GRAL 0.00
- ORIC -0.04
- Stochastic Oscillator
- GRAL 0.00
- ORIC 83.33
About GRAL GRAIL INC
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.